SBS Stock Overview
Designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for SBS from our risk checks.
Stratec SE Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €43.80 |
52 Week High | €51.40 |
52 Week Low | €36.00 |
Beta | 0.14 |
11 Month Change | 4.53% |
3 Month Change | -1.02% |
1 Year Change | -11.69% |
33 Year Change | -68.40% |
5 Year Change | -32.41% |
Change since IPO | 741.82% |
Recent News & Updates
Recent updates
Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year
May 11Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55
Apr 11Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
Apr 01Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55
Mar 28Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?
Dec 21Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Nov 03We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt
Oct 19Return Trends At Stratec (ETR:SBS) Aren't Appealing
Jul 12Stratec SE (ETR:SBS) Shares Could Be 43% Below Their Intrinsic Value Estimate
Jun 27Is Stratec (ETR:SBS) Using Too Much Debt?
May 25Stratec's (ETR:SBS) Upcoming Dividend Will Be Larger Than Last Year's
Apr 02The Returns At Stratec (ETR:SBS) Aren't Growing
Jan 28Calculating The Fair Value Of Stratec SE (ETR:SBS)
Jan 12Is Stratec (ETR:SBS) A Risky Investment?
Oct 26Returns On Capital At Stratec (ETR:SBS) Have Stalled
Oct 11Stratec (ETR:SBS) Has A Pretty Healthy Balance Sheet
Jul 23Should You Be Adding Stratec (ETR:SBS) To Your Watchlist Today?
Jul 07Stratec's (ETR:SBS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 12Stratec (ETR:SBS) Has Announced That It Will Be Increasing Its Dividend To €0.95
Apr 28Analysts Are Updating Their Stratec SE (ETR:SBS) Estimates After Its Annual Results
Apr 03Stratec's (ETR:SBS) Dividend Will Be Increased To €0.95
Apr 02These 4 Measures Indicate That Stratec (ETR:SBS) Is Using Debt Reasonably Well
Mar 13Stratec (ETR:SBS) Is Doing The Right Things To Multiply Its Share Price
Feb 12Do Stratec's (ETR:SBS) Earnings Warrant Your Attention?
Jan 27We Think Stratec (ETR:SBS) Can Stay On Top Of Its Debt
Dec 05Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Nov 02Do Stratec's (ETR:SBS) Earnings Warrant Your Attention?
Oct 18Is Stratec (ETR:SBS) Using Too Much Debt?
Sep 03Stratec (ETR:SBS) Will Want To Turn Around Its Return Trends
Aug 03Should You Be Adding Stratec (ETR:SBS) To Your Watchlist Today?
Jul 20Calculating The Intrinsic Value Of Stratec SE (ETR:SBS)
Jun 14Here's Why Stratec (ETR:SBS) Can Manage Its Debt Responsibly
May 31Here's Why Shareholders Will Not Be Complaining About Stratec SE's (ETR:SBS) CEO Pay Packet
May 13Shareholder Returns
SBS | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 5.5% | 2.7% | 3.3% |
1Y | -11.7% | 7.5% | 4.7% |
Return vs Industry: SBS underperformed the German Medical Equipment industry which returned 7.3% over the past year.
Return vs Market: SBS underperformed the German Market which returned 4.1% over the past year.
Price Volatility
SBS volatility | |
---|---|
SBS Average Weekly Movement | 4.3% |
Medical Equipment Industry Average Movement | 4.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.9% |
10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: SBS has not had significant price volatility in the past 3 months.
Volatility Over Time: SBS's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1979 | 1,464 | Marcus Wolfinger | www.stratec.com |
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018.
Stratec SE Fundamentals Summary
SBS fundamental statistics | |
---|---|
Market cap | €532.43m |
Earnings (TTM) | €14.58m |
Revenue (TTM) | €255.98m |
36.5x
P/E Ratio2.1x
P/S RatioIs SBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SBS income statement (TTM) | |
---|---|
Revenue | €255.98m |
Cost of Revenue | €186.66m |
Gross Profit | €69.33m |
Other Expenses | €54.75m |
Earnings | €14.58m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 25, 2024
Earnings per share (EPS) | 1.20 |
Gross Margin | 27.08% |
Net Profit Margin | 5.69% |
Debt/Equity Ratio | 23.4% |
How did SBS perform over the long term?
See historical performance and comparison